A. Sami Saribas

Consultant / Advisor at Ben Franklin Technology Partners /Ventures/

Consumer Services

Health Technology

Finance

Profile

Prior to joining Ben Franklin as an Advisor, Dr. Saribas was a Senior Scientist at Tetralogic Pharmaceuticals, Neose Technologies.
He was a Research Biochemist at University of Michigan Medical School.
Dr. Saribas earned a BS in Chemical Engineering from Yildiz Teknik Universitesi in 1982.
He earned an MS in Biochemistry from University of Missouri-Columbia in 1988.
Dr. Saribas earned a PhD in Chemistry and Biochemistry from the University of Akron in 1992.
He earned his Postdoc in Biology from University of Pennsylvania in 1997.

A. Sami Saribas active positions

Companies	Position	Start
Ben Franklin Technology Partners /Ventures/ Ben Franklin Technology Partners /Ventures/ Investment ManagersFinance Ben Franklin Technology Partners /Ventures/ (Ben Franklin Tech Partners) is a venture Capital firm founded in 1982. The firm is headquartered in Philadelphia, Pennsylvania.	Consultant / Advisor	-

All active positions of A. Sami Saribas

Former positions of A. Sami Saribas

Companies	Position	End
Neose Technologies, Inc. Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market.	Corporate Officer/Principal	-
Michigan Medicine	Corporate Officer/Principal	-
TETRALOGIC PHARMACEUTICALS CORPORATION	Corporate Officer/Principal	-

See the detail of A. Sami Saribas's experience

Training of A. Sami Saribas

University of Missouri	Graduate Degree
University of Akron	Doctorate Degree
University of Pennsylvania	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of A. Sami Saribas's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
TETRALOGIC PHARMACEUTICALS CORPORATION	Health Technology

Private companies	2
Ben Franklin Technology Partners /Ventures/ Ben Franklin Technology Partners /Ventures/ Investment ManagersFinance Ben Franklin Technology Partners /Ventures/ (Ben Franklin Tech Partners) is a venture Capital firm founded in 1982. The firm is headquartered in Philadelphia, Pennsylvania.	Finance
Neose Technologies, Inc. Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market.	Health Technology